Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hope for EoE patients: drug may allow return of favorite foods

NCT ID NCT05247866

Summary

This study tested if a medication called dupilumab could help children and young adults with eosinophilic esophagitis (EoE) safely reintroduce foods that normally trigger their condition. Participants aged 6 to 25 took dupilumab for 12 weeks to control their EoE. If their condition improved, they then tried slowly adding back common trigger foods like milk, egg, wheat, or soy while doctors monitored them with endoscopies over 48 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.